Thu Apr 02 05:46:03 UTC 2026: # Weight Loss and Diabetes Drugs Linked to Potential Eye Risks: Indian Ophthalmologists Issue Caution

The Story:
Indian ophthalmologists are raising concerns about the potential link between popular weight loss and blood sugar control drugs, specifically GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), and the worsening of diabetic retinopathy, and in rare cases, non-arteritic ischemic optic neuropathy (NAION), also known as an “eye stroke.” As semaglutide’s patent expires in March 2026, potentially leading to wider and more affordable access in India, medical experts urge caution and emphasize the need for careful patient evaluation and monitoring.

Key Points:

  • GLP-1 receptor agonists like semaglutide and tirzepatide are effective for weight loss and blood sugar control.
  • Ophthalmologists have observed a potential link between these drugs and the worsening of diabetic retinopathy and, rarely, NAION.
  • Rapid reductions in blood sugar levels triggered by these drugs may temporarily affect blood flow to the retina and optic nerve.
  • Individuals with pre-existing diabetic retinopathy, hypertension, sleep apnea, or specific optic nerve characteristics may be at higher risk.
  • Experts recommend detailed pre-treatment evaluations, including assessing systemic and ocular health, and close monitoring, especially during the early phase of treatment.
  • A collaborative approach between endocrinologists and ophthalmologists is crucial to minimizing risks.
  • Patients are cautioned against self-medication and should only undergo treatment under proper medical supervision.
  • Dr. Rohit Shetty, Director of Narayana Nethralaya, emphasizes balancing the benefits of these drugs with careful clinical judgment.
  • G. V. Divakar, past president of the Bangalore Ophthalmic Society, highlights the risk of permanent vision loss associated with NAION and the progression of diabetic retinopathy.
  • Rajesh R., consultant at Sankara Eye Hospital, notes that rapid improvement in blood glucose can temporarily worsen diabetic retinopathy, and further research is needed to establish a clear causal relationship between the drugs and optic nerve-related vision loss.

Key Takeaways:

  • The increasing use of GLP-1 receptor agonists for weight loss and diabetes management necessitates heightened awareness of potential ocular side effects.
  • Comprehensive pre-treatment assessment and ongoing monitoring are crucial for patients, particularly those with pre-existing risk factors.
  • Collaboration between endocrinologists and ophthalmologists is essential for optimal patient care and risk mitigation.
  • While the benefits of these drugs are significant, potential risks must be carefully considered and communicated to patients.
  • The expected increase in the availability of these medications in India following patent expiry requires strict medical supervision to prevent inappropriate use.

    Read More

Related News: